Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Stock markets moved in different directions Tuesday with traders' attention fixed on President-elect Donald Trump's tariff ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

For healthcare investors, though, it represented yet another reason to dump some stock. Trump’s appointment of industry ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

Thanks to a $2.5 million grant the museum received from Lilly Endowment Inc., expressions of religion and spirituality among ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

Shelby Knowles / Bloomberg via Getty Images Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive ...

The deal will open the door for the company to tap into an archive of more than 2,000 designs by Key West Hand Print Fabrics Co. and Suzie Zuzek.

Eli Lilly announced FDA approval of Zepbound as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea. In addition, adults on Zepbound lost an average of 45 ...